hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06345352 id: IRFMN_7520_PoliMI briefTitle: Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (Fondazione IRCCS Ca' Granda Ospedale Maggione Policlinico) overallStatus: ACTIVE_NOT_RECRUITING date: 2020-09-15 date: 2024-12 date: 2027-12 date: 2024-04-03 date: 2024-04-04 name: Mario Negri Institute for Pharmacological Research class: OTHER briefSummary: The aim of this study is to develop, study and validate a rigorous and sustainable method for assessing the clinical appropriateness of the decision taken in the Emergency Department to admit or not to admit patients. conditions: Quality of Care conditions: Evaluation conditions: Emergency Department conditions: Appropriateness studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1200 type: ESTIMATED measure: Algorithm creation measure: Algorithm validation measure: Algorithm application measure: Appropriateness estimation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano city: Milano state: MI zip: 20122 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06345326 id: E1-22-3155 briefTitle: Greater Occipital Nerve Block Versus Pulse Radiofrequency in Migraine acronym: GON-B/PRF overallStatus: RECRUITING date: 2023-01-15 date: 2024-03-30 date: 2024-04-30 date: 2024-04-03 date: 2024-04-03 name: Adiyaman University Research Hospital class: OTHER name: Ankara City Hospital Bilkent briefSummary: The aim of the study is to evaluate the clinical efficacy of the repeated greater occipital nerve(GON) blokcs with GON pulse radiofreaquency (PRF) conditions: Migraine studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective observational primaryPurpose: TREATMENT masking: NONE count: 68 type: ESTIMATED name: Greater occipital nerve block measure: NRS measure: Complications measure: the frequency of headhache sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara City Hospital Bilkent status: RECRUITING city: Ankara zip: 06680 country: Turkey name: Sukriye Dadali, MD role: CONTACT phone: +905333316636 email: sukriyedadali@gmail.com lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06345313 id: CIRCADIAN RHYTHM briefTitle: EFFECT OF CIRCADIAN RHYTHM ON INFLAMMATORY PARAMETERS IN UNILATERAL INGUINAL HERNIORRAHIES overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-09-15 date: 2024-10-15 date: 2024-04-03 date: 2024-04-03 name: Ankara City Hospital Bilkent class: OTHER briefSummary: To evaluate the inflammatory response of participants who will undergo unilateral inguinal hernia surgery at two different times of the day (08.00-12.00 during the day and 18.00-22.00 at night). The main question it aims to answer is; Is the inflammation response higher in participants who undergo surgery later in the day? Serum inflammatory parameters will be measured in both groups at the preoperative 1st hour and the postoperative 24th hour. conditions: Inflammatory Response studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 70 type: ESTIMATED name: Day Group name: Night Group measure: Change of IL6 (interleukin) (ng/ml) measure: Quality of recovery from anesthesia according to difference in circadian rhythm measure: Change of NLR ( Neutrophil/ Lymphocyte Ratio ) measure: Change of PLR ( Platelet / Lymphocyte Ratio ) measure: Change of SII (Systemic immune-inflammation index ) measure: Change of CRP (C Reactive Protein) (mg/dl) measure: Change of Fibrinogen (mg) measure: Change of Sedimentation (mm/hour) measure: Change of Procalcitonin (µg/l) measure: Change of Ferritin (ml/ng) measure: Postoperative pain scores according to the difference in circadian rhythm sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Bilkent City Hospital city: Ankara state: Cankaya zip: 06800 country: Turkey name: Burcu Dikmen Demiryorgan role: CONTACT phone: +905067611029 email: burcudikmen325@gmail.com name: Fatma Kavak Akelma role: CONTACT phone: +905327079113 email: fatmakavak@yahoo.com lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06345300 id: NCC4309 briefTitle: NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study overallStatus: RECRUITING date: 2024-03-10 date: 2024-12-12 date: 2025-12-24 date: 2024-04-03 date: 2024-04-03 name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences class: OTHER name: Jiangsu HengRui Medicine Co., Ltd. briefSummary: The aim of this study is to assess the efficacy and safety of Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab for patients with borderline resectable pancreatic cancer conditions: Borderline Resectable Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab name: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate measure: R0 resection rate measure: Event free survival (EFS) measure: Overall survival (OS) measure: Objective Response Rate(ORR) measure: Disease Control Rate（DCR） measure: Safety and tolerability by incidence, severity and outcome of adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Institute and Hospital, Chinese Academy of Medical Sciences status: RECRUITING city: Beijin country: China name: Yongkun Sun role: CONTACT phone: 13141276041 email: hsunyk@126.com hasResults: False
nctId: NCT06345287 id: 24/018-4298 briefTitle: Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC overallStatus: RECRUITING date: 2024-01-01 date: 2025-12-31 date: 2026-12-31 date: 2024-04-03 date: 2024-04-03 name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences class: OTHER briefSummary: The aim of this study is to develop an adaptive radiation therapy plan for locally advanced head and neck squamous cell carcinoma receiving induction therapy containing immunotherapy and chemotherapy. The therapy plan is based on clinical remission, in order to reduce treatment-related toxic side effects without sacrificing clinical efficacy and improve the quality of life of patients. conditions: Head and Neck Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 133 type: ESTIMATED name: radical radiotherapy (60Gy) name: radical radiotherapy (66Gy) name: radical radiotherapy (70Gy) name: anti-PD-1 or PD-L1 antibody measure: Progression-free survival measure: Overall survival measure: Deep partial response measure: Local-Regional failure survival measure: Toxicity Adverse events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC status: RECRUITING city: Beijing country: China name: Jingbo Wang, Doctor role: CONTACT phone: 15811166516 email: wangjingbo303@yahoo.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06345274 id: SP0077172 id: K23DA050729 type: NIH link: https://reporter.nih.gov/quickSearch/K23DA050729 briefTitle: MBC2OTP Project (Measurement-Based Care Implementation in Community Opioid Treatment Programs) acronym: MBC2OTP overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-02 date: 2026-02 date: 2024-04-03 date: 2024-04-22 name: Northwestern University class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: The goal of this clinical trial is to evaluate the effectiveness and implementation of measurement-based care, which involves the systematic use of client self-report data to inform and enhance treatment, in opioid treatment programs using a pilot hybrid effectiveness-implementation study design. The main questions this study aims to answer are: 1) is measurement based care effective for improving patient treatment attendance and opioid abstinence, and 2) can measurement based care be implemented with fidelity in opioid treatment programs? Participants in this study will be opioid treatment program leaders and treatment providers. Leaders and treatment providers will participate in measurement-based care implementation strategies such as training and consultation to help them use measurement-based care with their patients. There is no comparison group for this study, however researchers will compare effectiveness outcomes prior to and post measurement-based care implementation and will evaluate changes in measurement-based care use with fidelity post implementation. conditions: Opioid Use Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 40 type: ESTIMATED name: Measurement Based Care Training and Monthly Consultation measure: Patient treatment attendance (effectiveness outcome) measure: Patient treatment attendance (effectiveness outcome) measure: Treatment provider measurement based care exposure (implementation outcome) measure: Patient opioid abstinence (effectiveness outcome) measure: Treatment provider measurement based care fidelity (implementation outcome) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Family Guidance Centers, Inc. city: Aurora state: Illinois zip: 60505 country: United States lat: 41.76058 lon: -88.32007 facility: Northwestern University Feinberg School of Medicine city: Chicago state: Illinois zip: 60611 country: United States name: Kelli Scott, PhD role: CONTACT lat: 41.85003 lon: -87.65005 facility: Family Guidance Centers, Inc. city: Chicago state: Illinois zip: 60654 country: United States name: Kelli Scott, PhD role: CONTACT lat: 41.85003 lon: -87.65005 facility: Family Guidance Centers, Inc. city: Des Plaines state: Illinois zip: 60016 country: United States lat: 42.03336 lon: -87.8834 facility: Family Guidance Centers, Inc. city: Joliet state: Illinois zip: 60435 country: United States lat: 41.52519 lon: -88.0834 hasResults: False
nctId: NCT06345261 id: 2024-872 briefTitle: Diphenhydramine in Catheter Related Bladder Discomfort overallStatus: ENROLLING_BY_INVITATION date: 2024-04-01 date: 2025-04-01 date: 2025-05-01 date: 2024-04-03 date: 2024-04-03 name: Cairo University class: OTHER briefSummary: Diphenhydramine has H1-antihistamine action, it also possesses anti-muscarinic properties. Thus, diphenhydramine might be able to reduce the problem of catheter related bladder discomfort by inhibiting smooth muscle spasm of the urinary bladder via its anti-muscarinic action . conditions: Catheter Complications studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 104 type: ESTIMATED name: DiphenhydrAMINE 50 Mg/mL Injectable Solution name: Saline measure: incidence of catheter related bladder discomfort postoperative measure: visual analog scale (VAS) sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo university city: Cairo zip: 11562 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06345248 id: 2024-854 briefTitle: Laparoscopic-assisted Versus Ultrasonography-guided Transversus Abdominis Plane Block in Laparoscopic Sleeve Gastrectomy overallStatus: ENROLLING_BY_INVITATION date: 2024-04-01 date: 2025-04-01 date: 2025-05-01 date: 2024-04-03 date: 2024-04-03 name: Cairo University class: OTHER briefSummary: The transversus abdominis plane (TAP) block, whereby local anesthetic is injected between the internal oblique and transversus abdominis fascia to facilitate blockade of somatic afferents nerves, is an effective, non-narcotic adjunct incorporated into many ERAS protocols. We hypothesized that surgeon delivered LAP-TAPs would be non-inferior to anesthesia-delivered US-TAPs in terms of post-operative pain control conditions: Transversus Abdominis Plane studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 74 type: ESTIMATED name: US-TAP name: LAPTAP measure: morphine needed measure: first analgesic request time measure: patients' satisfaction measure: opioid-associated side effects sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo university city: Cairo zip: 11562 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06345235 id: ID DEC-2023/07/X/NZ5/00141 briefTitle: New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis overallStatus: RECRUITING date: 2023-07-11 date: 2024-07-11 date: 2024-07-11 date: 2024-04-03 date: 2024-04-19 name: John Paul II Hospital, Krakow class: OTHER briefSummary: The development of cardiac amyloidosis is caused by the deposition of misfolded, insoluble proteins in the extracellular matrix of tissues. An important element of the clinical picture of the disease is the increased risk of thromboembolic complications, independent of the occurrence of atrial fibrillation, and the presence of intracardiac thrombi. The pathomechanism may be related to an increase in filling pressure or amyloid infiltration leading to myocardial damage and endothelial dysfunction, which may activate the prothrombotic inflammatory cascade, resulting in increased thrombogenic potential. Currently, there is limited published data on the potential role of new heart failure biomarkers in the assessment of ATTR cardiomyopathy, particularly in the assessment of asymptomatic carriers of pathogenic TTR variants. Moreover, there are few literature reports on the direct assessment of the coagulation system in this group of patients, and the pathomechanism of the increased thromboembolic risk is unexplored.
Purpose of the study: To assess the diagnostic value of biomarkers related to heart failure (growth differentiation factor-15 (GDF15), soluble suppression of tumorigenicity-2 (ST2), galectin-3), amyloidosis ( TTR, tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-9 (MMP-9, matrix metalloproteinase-9), neurofilament light chain (NfL)) and the generation potential thrombin as a marker of the prothrombotic state in the course of ATTR.
Methods: This prospective, single-center study will include consecutive patients diagnosed with ATTR cardiomyopathy (GROUP 1, n=30), asymptomatic carriers of pathogenic TTR variants (GROUP 2, n=30), and a matched control group of healthy volunteers (GROUP 3 , n=20). Material for research was collected and secured from all study participants. After giving informed consent, all patients will be tested using the ELISA method from peripheral blood (enzyme-linked immunosorbent assay) GDF15, ST2, TTR, TIMP-1, MMP-9, galectin-3, NfL. The values of these biomarkers will be compared in subgroups and correlated with clinical data, laboratory test results, echocardiography including analysis of left ventricular global strain (GLS), and scintigraphy. Additionally, the prothrombotic potential of plasma will be tested in both groups of patients using the calibrated automatic thrombogram (CAT) method, in accordance with the protocol previously used in the laboratory Expected results: The project will provide information on the value of biomarkers in the assessment of ATTR cardiomyopathy, especially in the assessment of asymptomatic carriers of pathogenic TTR variants, which may translate into the creation of a diagnostic algorithm for early identification of the development of the disease. Moreover, it will allow us to determine whether patients with cardiac ATTR are characterized by a prothrombotic state, which has not yet been described in the literature and may have potential clinical implications. conditions: Transthyretin Amyloidosis studyType: OBSERVATIONAL observationalModel: FAMILY_BASED timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: blood test measure: Biomarkers measure: Thrombin as a marker measure: Biomarkers measure: Biomarkers measure: Biomarkers measure: Biomarkers measure: Biomarkers measure: Biomarkers sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: John Paul II Hospital status: RECRUITING city: Kraków zip: 31-202 country: Poland name: Katarzyna Holcman, MD role: CONTACT phone: 608214249 phoneExt: 48 email: katarzyna.holcman@gmail.com name: Katarzyna Holcman, MD role: PRINCIPAL_INVESTIGATOR lat: 50.06143 lon: 19.93658 hasResults: False
nctId: NCT06345222 id: GETAT 23/05 briefTitle: Examining the Effect of Prolotherapy on Quality of Life and Painkiller Use in Patients With Knee Pain overallStatus: COMPLETED date: 2023-05-01 date: 2023-07-31 date: 2023-07-31 date: 2024-04-03 date: 2024-04-04 name: Bursa Yüksek İhtisas Education and Research Hospital class: OTHER_GOV briefSummary: 92 patients with a diagnosis of primary knee pain of unknown cause followed at the family medicine outpatient clinic and who met our exclusion criteria were invited to the study. When creating patient list, the examination of patients, interviews with patients, as well as their medical records and examinations were used. Patients were divided into two groups: prolotherapy (n=46) and control group (n=46) by simple randomization method. However, when the study started, 32 people in the prolotherapy group and 33 people in the control group of these patients participated in the study. Prior to the research, detailed information was provided about the research in the experimental and control groups and signed consent was obtained from all participants that they volunteered to participate in the research. 5% dectrose was applied to the prolotherapy group by injection method to the pain area. In the control group, existing medical treatments were continued and no injection procedure was performed. Before the research, all participants were evaluated with Case Report Form, Visual Analog Scale (VAS) and Quality of Life Scale Short Form (SF-36). The cases in the experimental and control groups were re-evaluated with the VAS and SF-36 scales at the first month. conditions: The Aim of This Research is to Investigate the Effect of Prolotherapy on Quality of Life and Painkiller Use in Patients With Chronic Knee Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Case control study primaryPurpose: TREATMENT masking: NONE count: 65 type: ACTUAL name: Prolotherapy measure: change in knee pain with prolotherapy application measure: change in quality of life sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bursa Yuksek Ihtisas Training and Research Hospital city: Bursa state: Türkiye zip: 16310 country: Turkey lat: 40.19559 lon: 29.06013 hasResults: False
nctId: NCT06345209 id: BM-D19 briefTitle: Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for Coronary Small Vessels overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2025-12 date: 2024-04-03 date: 2024-04-03 name: BrosMed Medical Co., Ltd class: INDUSTRY name: Chinese Academy of Medical Sciences, Fuwai Hospital briefSummary: To evaluate the safety and efficacy of a sirolimus-coated coronary balloon dilatation catheter for the treatment of small vessel lesions of primary coronary arteries. conditions: Coronary Artery Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 236 type: ESTIMATED name: Sirolimus-coated Coronary Balloon Dilatation Catheter name: Drug-coated Coronary Balloon Dilatation Catheter measure: Late luminal loss (LLL) measure: Device success rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06345196 id: BozokUni briefTitle: Motivational Interviewing Applied to Individuals With Diabetes overallStatus: RECRUITING date: 2024-04-15 date: 2024-05-15 date: 2024-10-15 date: 2024-04-03 date: 2024-04-03 name: Bozok University class: OTHER briefSummary: This study will be conducted using a randomized controlled trial design to evaluate the effect of online individual motivational interviewing on well-being, stress and difficulties in individuals with diabetes. The study will be conducted between March 2024 and March 2025 with individuals with Type 2 Diabetes who are followed up in Yozgat Bozok University Health Practice and Research Center Internal Medicine Polyclinic. The motivational interview group will receive a motivational interview once a week, lasting a maximum of 40 minutes, consisting of a total of four sessions. Chi-square (X2), t-test, repeated measures analysis of variance, Pearson correlation coefficient, partial eta-square and linear regression analysis will be used to evaluate the data. conditions: Motivational Interviewing conditions: Stress conditions: Well-Being, Psychological conditions: Diabetes Mellitus conditions: Type2diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 66 type: ESTIMATED name: motivational interview measure: Change in coping with stress measure: State of Well-Being Change measure: Changing Strength and Difficulties in Diabetes sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Akdağmadeni School of Health status: RECRUITING city: Yozgat country: Turkey name: Betül Bal role: CONTACT phone: 0 (354) 314 14 15 email: betul.bal@yobu.edu.tr lat: 39.82 lon: 34.80444 facility: Bozok University status: RECRUITING city: Yozgat country: Turkey name: Betül Bal role: CONTACT phone: 0 (354) 314 14 15 email: betul.bal@yobu.edu.tr lat: 39.82 lon: 34.80444 hasResults: False